SCHEMBL4917385

SCHEMBL4917385

CC(Oc1ccc(Br)cc1)C(=O)Nc1ccccc1C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.66
TDP1 Q9NUW8 3/20 0.66
KDM4E B2RXH2 1/20 0.64
HTT P42858 1/20 0.64
ALDH1A1 P00352 2/20 0.60
MAPK1 P28482 1/20 0.60
HPGD P15428 1/20 0.59
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.54
TRPA1 O75762 1/20 0.49
TRPM8 Q7Z2W7 1/20 0.49
OPRK1 P41145 1/20 0.48
DHODH Q02127 1/20 0.48
APOBEC3A P31941 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
MAPT P10636 1/20 0.47
TEAD4 Q15561 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5065560 0.88 TSHR (0.67) TSHRTDP1KDM4EHTTALDH1A1
SCHEMBL4912839 0.87 TSHR (0.66) TSHRTDP1KDM4EHTTALDH1A1
SCHEMBL4916080 0.79 TSHR (0.67) TSHRTDP1KDM4EHTTALDH1A1
SCHEMBL8027746 0.76 ALDH1A1 (0.55) TSHRTDP1KDM4EHTTALDH1A1
SCHEMBL27520066 0.76 KMT2A (0.65) ALDH1A1HPGDMEN1KMT2ATRPA1
SCHEMBL28575819 0.76 LMNA (0.69) TSHRTDP1HTTALDH1A1HPGD
SCHEMBL28575820 0.76 LMNA (0.69) TSHRTDP1HTTALDH1A1HPGD
SCHEMBL28577769 0.74 GAA (0.76) TSHRTDP1KDM4EHTTALDH1A1
SCHEMBL140910 0.74 KMT2A (0.54) TSHRTDP1KDM4EHTTMEN1
SCHEMBL27972037 0.74 KMT2A (0.54) TSHRTDP1KDM4EHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US claimed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US claimed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US claimed
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US disclosed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US disclosed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US disclosed
WO-2004091724-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus HCCS, ALAD, HAVCR2 TSHR 4195/4885TDP1 4850/4885KDM4E 2214/4885
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS HCCS, ALAD, HAVCR2 TSHR 4195/4885TDP1 4850/4885KDM4E 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.